THE PHARMACOKINETICS OF NICOTINAMIDE IN HUMANS AND RODENTS

被引:35
作者
PETLEY, A
MACKLIN, B
RENWICK, AG
WILKIN, TJ
机构
[1] UNIV PLYMOUTH,DEPT MED,PLYMOUTH PL4 8AA,DEVON,ENGLAND
[2] UNIV SOUTHAMPTON,SOUTHAMPTON,HANTS,ENGLAND
基金
英国惠康基金;
关键词
D O I
10.2337/diabetes.44.2.152
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nicotinamide, a derivative of the B vitamin niacin, is currently under trial for the prevention of insulin-dependent diabetes mellitus after success in the NOD mouse. However, the dose, route of administration, and formulation of nicotinamide given to humans is quite different from those used successfully in animals, and the aim of this study was to investigate the plasma pharmacokinetics of oral nicotinamide in humans in two doses and in two different formulations (standard and the long-acting Enduramide). There were no significant differences in the kinetics of the low dose of standard nicotinamide (2.5 mg/kg) and low-dose Enduramide (6.7 mg/kg) in young adult men, Nonlinear kinetics were found with both formulations at higher doses, e.g., a 10-fold increase in the dose of the standard nicotinamide produced a 62-fold increase in the area under the plasma concentration-time curve (AUC). The high dose of standard nicotinamide (25 mg/kg body wt) produced a mean peak plasma concentration 75% higher than that achieved with the sustained release nicotinamide preparation given in a dose similar to that currently used in prevention trials (2 g = 26.6 mg/kg body wt for a 75-kg subject). The AUC was also significantly greater with the standard formulation, indicating a higher bioavailability. Long-term plasma levels for high doses of both formulations were modeled from the single-dose kinetics by computer program. The AUC for standard nicotinamide was 1.7 times higher than that for Enduramide. We conclude that standard nicotinamide offers greater bioavailability than the long-acting formulation tested and that the metabolic clearance pathways of nicotinamide are saturated at the doses currently used in human trials.
引用
收藏
页码:152 / 155
页数:4
相关论文
共 15 条
[1]   NICOTINAMIDE PREVENTS INTERLEUKIN-1 EFFECTS ON ACCUMULATED INSULIN RELEASE AND NITRIC-OXIDE PRODUCTION IN RAT ISLETS OF LANGERHANS [J].
ANDERSEN, HU ;
JORGENSEN, KH ;
EGEBERG, J ;
MANDRUPPOULSEN, T ;
NERUP, J .
DIABETES, 1994, 43 (06) :770-777
[2]   A TRIAL OF NICOTINAMIDE IN NEWLY DIAGNOSED PATIENTS WITH TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS [J].
CHASE, HP ;
BUTLERSIMON, N ;
GARG, S ;
MCDUFFIE, M ;
HOOPS, SL ;
OBRIEN, D .
DIABETOLOGIA, 1990, 33 (07) :444-446
[3]   DETERMINATION OF NICOTINAMIDE IN HUMAN-PLASMA AND URINE BY ION-PAIR REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
DEVRIES, JX ;
GUNTHERT, W ;
DING, R .
JOURNAL OF CHROMATOGRAPHY, 1980, 221 (01) :161-165
[4]   PREVENTION OR DELAY OF TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS IN CHILDREN USING NICOTINAMIDE [J].
ELLIOTT, RB ;
CHASE, HP .
DIABETOLOGIA, 1991, 34 (05) :362-365
[5]  
ELLIOTT RB, 1991, DIABETES RES CLIN S, V14, P585
[6]  
HANDLER P, 1942, J BIOL CHEM, V146, P359
[7]   METHYLATED NIACIN DERIVATIVES IN PLASMA AND URINE AFTER AN ORAL DOSE OF NICOTINAMIDE GIVEN TO SUBJECTS FED A LOW-METHIONINE DIET [J].
JENKS, BH ;
MCKEE, RW ;
SWENDSEID, ME ;
FARAJI, B ;
FIGUEROA, WG ;
CLEMENS, RA .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1987, 46 (03) :496-502
[8]   METABOLIC EFFECTS OF NICOTINAMIDE ADMINISTRATION IN RATS [J].
KANGLEE, YA ;
MCKEE, RW ;
WRIGHT, SM ;
SWENDSEID, ME ;
JENDEN, DJ ;
JOPE, RS .
JOURNAL OF NUTRITION, 1983, 113 (02) :215-221
[9]   MECHANISMS OF NICOTINAMIDE AND THYMIDINE PROTECTION FROM ALLOXAN AND STREPTOZOCIN TOXICITY [J].
LEDOUX, SP ;
HALL, CR ;
FORBES, PM ;
PATTON, NJ ;
WILSON, GL .
DIABETES, 1988, 37 (08) :1015-1019
[10]   COMPARATIVE STUDIES IN NIACIN METABOLISM - THE FATE OF NIACIN IN MAN, RAT, DOG, PIG, RABBIT, GUINEA PIG, GOAT, SHEEP AND CALF [J].
PERLZWEIG, WA ;
ROSEN, F ;
PEARSON, PB .
JOURNAL OF NUTRITION, 1950, 40 (03) :453-469